Prognostic and therapeutic implications of microRNA in malignant pleural mesothelioma

Anna Truini, Simona Coco, Carlo Genova, Marco Mora, Maria G. Dal Bello, Irene Vanni, Angela Alama, Erika Rijavec, Giulia Barletta, Federica Biello, Claudia Maggioni, Francesco Grossi

Research output: Contribution to journalReview article

Abstract

Malignant Pleural Mesothelioma (MPM) is an aggressive disease characterized by a dismal prognosis, mainly due to late diagnosis. To date, there are very few treatment options available and the refractoriness to the majority of therapeutic strategies, leading to consider MPM a relevant problem in public health. Therefore, the identification of novel prognostic markers and alternative therapeutic strategies remain a top priority. Several efforts have been made in this direction and to date a number of studies have investigated the role of microRNA as biomarkers in MPM, identifying the potential prognostic role of miR-29c* and miR-31. Very recently, the first microRNA signature able to discriminate poor or and good prognosis of MPM patients underwent surgery has been published. Very interestingly, several microRNA such as miR-1, miR-16, and miR-34b/c have been identified as potential therapeutic agents. Indeed, the forced expression of these microRNA resulted in anti-tumor effects both in vitro and in vivo. Besides, the introduction of microRNA mimic, some agents such as EphrinA1 and Onconase, seemed to exert anti-tumor effects through specific microRNA. Moreover, microRNA have also been reported to play a role in chemoresistance enhancing the sensitivity to specific drug such as pemetrexed. In this review the most relevant and updated data about the role of microRNA as prognostic markers and therapeutic agents in MPM will be presented, opening new avenues towards improved management of this aggressive disease.

Original languageEnglish
Pages (from-to)12-18
Number of pages7
JournalMicroRNA
Volume5
Issue number1
DOIs
Publication statusPublished - Apr 1 2016

Fingerprint

MicroRNAs
Therapeutics
Pemetrexed
Malignant Mesothelioma
Delayed Diagnosis
Disease Management
Neoplasms
Public Health
Biomarkers
Pharmaceutical Preparations

Keywords

  • Malignant pleural mesothelioma
  • microRNA
  • Prognosis
  • Prognostic signature
  • Therapeutic
  • Tumor suppressor microRNA

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Prognostic and therapeutic implications of microRNA in malignant pleural mesothelioma. / Truini, Anna; Coco, Simona; Genova, Carlo; Mora, Marco; Dal Bello, Maria G.; Vanni, Irene; Alama, Angela; Rijavec, Erika; Barletta, Giulia; Biello, Federica; Maggioni, Claudia; Grossi, Francesco.

In: MicroRNA, Vol. 5, No. 1, 01.04.2016, p. 12-18.

Research output: Contribution to journalReview article

Truini, A, Coco, S, Genova, C, Mora, M, Dal Bello, MG, Vanni, I, Alama, A, Rijavec, E, Barletta, G, Biello, F, Maggioni, C & Grossi, F 2016, 'Prognostic and therapeutic implications of microRNA in malignant pleural mesothelioma', MicroRNA, vol. 5, no. 1, pp. 12-18. https://doi.org/10.2174/2211536605666160128151018
Truini, Anna ; Coco, Simona ; Genova, Carlo ; Mora, Marco ; Dal Bello, Maria G. ; Vanni, Irene ; Alama, Angela ; Rijavec, Erika ; Barletta, Giulia ; Biello, Federica ; Maggioni, Claudia ; Grossi, Francesco. / Prognostic and therapeutic implications of microRNA in malignant pleural mesothelioma. In: MicroRNA. 2016 ; Vol. 5, No. 1. pp. 12-18.
@article{c72058b03f934cd3bea4f02c059f21a5,
title = "Prognostic and therapeutic implications of microRNA in malignant pleural mesothelioma",
abstract = "Malignant Pleural Mesothelioma (MPM) is an aggressive disease characterized by a dismal prognosis, mainly due to late diagnosis. To date, there are very few treatment options available and the refractoriness to the majority of therapeutic strategies, leading to consider MPM a relevant problem in public health. Therefore, the identification of novel prognostic markers and alternative therapeutic strategies remain a top priority. Several efforts have been made in this direction and to date a number of studies have investigated the role of microRNA as biomarkers in MPM, identifying the potential prognostic role of miR-29c* and miR-31. Very recently, the first microRNA signature able to discriminate poor or and good prognosis of MPM patients underwent surgery has been published. Very interestingly, several microRNA such as miR-1, miR-16, and miR-34b/c have been identified as potential therapeutic agents. Indeed, the forced expression of these microRNA resulted in anti-tumor effects both in vitro and in vivo. Besides, the introduction of microRNA mimic, some agents such as EphrinA1 and Onconase, seemed to exert anti-tumor effects through specific microRNA. Moreover, microRNA have also been reported to play a role in chemoresistance enhancing the sensitivity to specific drug such as pemetrexed. In this review the most relevant and updated data about the role of microRNA as prognostic markers and therapeutic agents in MPM will be presented, opening new avenues towards improved management of this aggressive disease.",
keywords = "Malignant pleural mesothelioma, microRNA, Prognosis, Prognostic signature, Therapeutic, Tumor suppressor microRNA",
author = "Anna Truini and Simona Coco and Carlo Genova and Marco Mora and {Dal Bello}, {Maria G.} and Irene Vanni and Angela Alama and Erika Rijavec and Giulia Barletta and Federica Biello and Claudia Maggioni and Francesco Grossi",
year = "2016",
month = "4",
day = "1",
doi = "10.2174/2211536605666160128151018",
language = "English",
volume = "5",
pages = "12--18",
journal = "MicroRNA (Shariqah, United Arab Emirates)",
issn = "2211-5366",
publisher = "Bentham Science Publishers",
number = "1",

}

TY - JOUR

T1 - Prognostic and therapeutic implications of microRNA in malignant pleural mesothelioma

AU - Truini, Anna

AU - Coco, Simona

AU - Genova, Carlo

AU - Mora, Marco

AU - Dal Bello, Maria G.

AU - Vanni, Irene

AU - Alama, Angela

AU - Rijavec, Erika

AU - Barletta, Giulia

AU - Biello, Federica

AU - Maggioni, Claudia

AU - Grossi, Francesco

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Malignant Pleural Mesothelioma (MPM) is an aggressive disease characterized by a dismal prognosis, mainly due to late diagnosis. To date, there are very few treatment options available and the refractoriness to the majority of therapeutic strategies, leading to consider MPM a relevant problem in public health. Therefore, the identification of novel prognostic markers and alternative therapeutic strategies remain a top priority. Several efforts have been made in this direction and to date a number of studies have investigated the role of microRNA as biomarkers in MPM, identifying the potential prognostic role of miR-29c* and miR-31. Very recently, the first microRNA signature able to discriminate poor or and good prognosis of MPM patients underwent surgery has been published. Very interestingly, several microRNA such as miR-1, miR-16, and miR-34b/c have been identified as potential therapeutic agents. Indeed, the forced expression of these microRNA resulted in anti-tumor effects both in vitro and in vivo. Besides, the introduction of microRNA mimic, some agents such as EphrinA1 and Onconase, seemed to exert anti-tumor effects through specific microRNA. Moreover, microRNA have also been reported to play a role in chemoresistance enhancing the sensitivity to specific drug such as pemetrexed. In this review the most relevant and updated data about the role of microRNA as prognostic markers and therapeutic agents in MPM will be presented, opening new avenues towards improved management of this aggressive disease.

AB - Malignant Pleural Mesothelioma (MPM) is an aggressive disease characterized by a dismal prognosis, mainly due to late diagnosis. To date, there are very few treatment options available and the refractoriness to the majority of therapeutic strategies, leading to consider MPM a relevant problem in public health. Therefore, the identification of novel prognostic markers and alternative therapeutic strategies remain a top priority. Several efforts have been made in this direction and to date a number of studies have investigated the role of microRNA as biomarkers in MPM, identifying the potential prognostic role of miR-29c* and miR-31. Very recently, the first microRNA signature able to discriminate poor or and good prognosis of MPM patients underwent surgery has been published. Very interestingly, several microRNA such as miR-1, miR-16, and miR-34b/c have been identified as potential therapeutic agents. Indeed, the forced expression of these microRNA resulted in anti-tumor effects both in vitro and in vivo. Besides, the introduction of microRNA mimic, some agents such as EphrinA1 and Onconase, seemed to exert anti-tumor effects through specific microRNA. Moreover, microRNA have also been reported to play a role in chemoresistance enhancing the sensitivity to specific drug such as pemetrexed. In this review the most relevant and updated data about the role of microRNA as prognostic markers and therapeutic agents in MPM will be presented, opening new avenues towards improved management of this aggressive disease.

KW - Malignant pleural mesothelioma

KW - microRNA

KW - Prognosis

KW - Prognostic signature

KW - Therapeutic

KW - Tumor suppressor microRNA

UR - http://www.scopus.com/inward/record.url?scp=85017492367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017492367&partnerID=8YFLogxK

U2 - 10.2174/2211536605666160128151018

DO - 10.2174/2211536605666160128151018

M3 - Review article

C2 - 26817512

AN - SCOPUS:85017492367

VL - 5

SP - 12

EP - 18

JO - MicroRNA (Shariqah, United Arab Emirates)

JF - MicroRNA (Shariqah, United Arab Emirates)

SN - 2211-5366

IS - 1

ER -